Targeted therapy in malignant mesothelioma

Malignant mesothelioma is a highly aggressive neoplasm of serosal surfaces, such as the pleura and the peritoneum. Its incidence is increasing worldwide, due to a widespread exposure to asbestos. Aggressive multimodal strategies including pleuropneumonectomy are under evaluation but concern selected...

Full description

Saved in:
Bibliographic Details
Published in:Targeted oncology 2008-07, Vol.3 (3), p.217-221
Main Author: Bréchot, Jeanne-Marie
Format: Article
Language:English
Subjects:
Biomedicine
Cancer
Chemotherapy
Medicine
Medicine & Public Health
Oncology
Review
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c268t-83968afe7f880af0bffce5e531d2575a0270aabb539c1ea88b1fb197d4a426c3
container_end_page 221
container_issue 3
container_start_page 217
container_title Targeted oncology
container_volume 3
creator Bréchot, Jeanne-Marie
description Malignant mesothelioma is a highly aggressive neoplasm of serosal surfaces, such as the pleura and the peritoneum. Its incidence is increasing worldwide, due to a widespread exposure to asbestos. Aggressive multimodal strategies including pleuropneumonectomy are under evaluation but concern selected patients and rarely permit a long-term survival. Numerous chemotherapy agents have been tested, alone or in combination. The doublet cisplatin–pemetrexed has emerged as the chemotherapy standard in this disease. However, the benefit of this regimen remains modest. Emerging targeted therapies in oncology accompany a better knowledge of tumor biology. This paper sums up the knowledge in malignant mesothelioma biology and the results of the few trials with targeted therapies conducted in this devastating disease.
doi_str_mv 10.1007/s11523-008-0089-2
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1112235593</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2789647101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c268t-83968afe7f880af0bffce5e531d2575a0270aabb539c1ea88b1fb197d4a426c3</originalsourceid><addsrcrecordid>eNp1kEFLxDAQhYMouK7-AG8Fb0J0Jtk0yVEWXYUFLz14C9M2Wbts2zXpHvbf26UKXjw8ZmDeewMfY7cIDwigHxOiEpIDmJMsF2dshlrnXOTwcf67K5tfsquUtgALLRTM2H1BceMHX2fDp4-0P2ZNl7W0azYddUPW-tSPh13Tt3TNLgLtkr_5mXNWvDwXy1e-fl-9LZ_WvBK5GbiRNjcUvA7GAAUoQ6i88kpiLZRWBEIDUVkqaSv0ZEyJoUSr6wUtRF7JObubavex_zr4NLhtf4jd-NEhohBSKStHF06uKvYpRR_cPjYtxaNDcCcibiLiRhonWSfGjJgyafR2Gx__NP8b-gaVOmLu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1112235593</pqid></control><display><type>article</type><title>Targeted therapy in malignant mesothelioma</title><source>Springer Nature</source><creator>Bréchot, Jeanne-Marie</creator><creatorcontrib>Bréchot, Jeanne-Marie</creatorcontrib><description>Malignant mesothelioma is a highly aggressive neoplasm of serosal surfaces, such as the pleura and the peritoneum. Its incidence is increasing worldwide, due to a widespread exposure to asbestos. Aggressive multimodal strategies including pleuropneumonectomy are under evaluation but concern selected patients and rarely permit a long-term survival. Numerous chemotherapy agents have been tested, alone or in combination. The doublet cisplatin–pemetrexed has emerged as the chemotherapy standard in this disease. However, the benefit of this regimen remains modest. Emerging targeted therapies in oncology accompany a better knowledge of tumor biology. This paper sums up the knowledge in malignant mesothelioma biology and the results of the few trials with targeted therapies conducted in this devastating disease.</description><identifier>ISSN: 1776-2596</identifier><identifier>EISSN: 1776-260X</identifier><identifier>DOI: 10.1007/s11523-008-0089-2</identifier><language>eng</language><publisher>Paris: Springer-Verlag</publisher><subject>Biomedicine ; Cancer ; Chemotherapy ; Medicine ; Medicine &amp; Public Health ; Oncology ; Review</subject><ispartof>Targeted oncology, 2008-07, Vol.3 (3), p.217-221</ispartof><rights>Springer-Verlag 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c268t-83968afe7f880af0bffce5e531d2575a0270aabb539c1ea88b1fb197d4a426c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Bréchot, Jeanne-Marie</creatorcontrib><title>Targeted therapy in malignant mesothelioma</title><title>Targeted oncology</title><addtitle>Targ Oncol</addtitle><description>Malignant mesothelioma is a highly aggressive neoplasm of serosal surfaces, such as the pleura and the peritoneum. Its incidence is increasing worldwide, due to a widespread exposure to asbestos. Aggressive multimodal strategies including pleuropneumonectomy are under evaluation but concern selected patients and rarely permit a long-term survival. Numerous chemotherapy agents have been tested, alone or in combination. The doublet cisplatin–pemetrexed has emerged as the chemotherapy standard in this disease. However, the benefit of this regimen remains modest. Emerging targeted therapies in oncology accompany a better knowledge of tumor biology. This paper sums up the knowledge in malignant mesothelioma biology and the results of the few trials with targeted therapies conducted in this devastating disease.</description><subject>Biomedicine</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Review</subject><issn>1776-2596</issn><issn>1776-260X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp1kEFLxDAQhYMouK7-AG8Fb0J0Jtk0yVEWXYUFLz14C9M2Wbts2zXpHvbf26UKXjw8ZmDeewMfY7cIDwigHxOiEpIDmJMsF2dshlrnXOTwcf67K5tfsquUtgALLRTM2H1BceMHX2fDp4-0P2ZNl7W0azYddUPW-tSPh13Tt3TNLgLtkr_5mXNWvDwXy1e-fl-9LZ_WvBK5GbiRNjcUvA7GAAUoQ6i88kpiLZRWBEIDUVkqaSv0ZEyJoUSr6wUtRF7JObubavex_zr4NLhtf4jd-NEhohBSKStHF06uKvYpRR_cPjYtxaNDcCcibiLiRhonWSfGjJgyafR2Gx__NP8b-gaVOmLu</recordid><startdate>20080701</startdate><enddate>20080701</enddate><creator>Bréchot, Jeanne-Marie</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20080701</creationdate><title>Targeted therapy in malignant mesothelioma</title><author>Bréchot, Jeanne-Marie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c268t-83968afe7f880af0bffce5e531d2575a0270aabb539c1ea88b1fb197d4a426c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biomedicine</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bréchot, Jeanne-Marie</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Targeted oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bréchot, Jeanne-Marie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted therapy in malignant mesothelioma</atitle><jtitle>Targeted oncology</jtitle><stitle>Targ Oncol</stitle><date>2008-07-01</date><risdate>2008</risdate><volume>3</volume><issue>3</issue><spage>217</spage><epage>221</epage><pages>217-221</pages><issn>1776-2596</issn><eissn>1776-260X</eissn><abstract>Malignant mesothelioma is a highly aggressive neoplasm of serosal surfaces, such as the pleura and the peritoneum. Its incidence is increasing worldwide, due to a widespread exposure to asbestos. Aggressive multimodal strategies including pleuropneumonectomy are under evaluation but concern selected patients and rarely permit a long-term survival. Numerous chemotherapy agents have been tested, alone or in combination. The doublet cisplatin–pemetrexed has emerged as the chemotherapy standard in this disease. However, the benefit of this regimen remains modest. Emerging targeted therapies in oncology accompany a better knowledge of tumor biology. This paper sums up the knowledge in malignant mesothelioma biology and the results of the few trials with targeted therapies conducted in this devastating disease.</abstract><cop>Paris</cop><pub>Springer-Verlag</pub><doi>10.1007/s11523-008-0089-2</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1776-2596
ispartof Targeted oncology, 2008-07, Vol.3 (3), p.217-221
issn 1776-2596
1776-260X
language eng
recordid cdi_proquest_journals_1112235593
source Springer Nature
subjects Biomedicine
Cancer
Chemotherapy
Medicine
Medicine & Public Health
Oncology
Review
title Targeted therapy in malignant mesothelioma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T21%3A19%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20therapy%20in%20malignant%20mesothelioma&rft.jtitle=Targeted%20oncology&rft.au=Br%C3%A9chot,%20Jeanne-Marie&rft.date=2008-07-01&rft.volume=3&rft.issue=3&rft.spage=217&rft.epage=221&rft.pages=217-221&rft.issn=1776-2596&rft.eissn=1776-260X&rft_id=info:doi/10.1007/s11523-008-0089-2&rft_dat=%3Cproquest_cross%3E2789647101%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c268t-83968afe7f880af0bffce5e531d2575a0270aabb539c1ea88b1fb197d4a426c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1112235593&rft_id=info:pmid/&rfr_iscdi=true